ストックスクリーナーアプリを入手
0.5623
0.52%
0.0029
アフターアワーズ：
.56
-0.0023
-0.41%
Hoth Therapeutics Inc (HOTH) 最新ニュース
Trend Report: Is Hoth Therapeutics Inc stock trending bullish2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
HOTH.O Forecast — Price Prediction for 2026. Should I Buy HOTH.O? - Intellectia AI
HOTH.O - Reuters
Guidance Update: Whats the fair value of Hoth Therapeutics Inc stock2026 Earnings Surprises & Stock Timing and Entry Methods - baoquankhu1.vn
Hoth Therapeutics Completes Registered Direct Offering Financing - The Globe and Mail
Hoth Therapeutics, Inc. (HOTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hoth Therapeutics, Inc. (HOTH) stock price, news, quote and history - Yahoo Finance UK
Hoth Therapeutics closes $2 million registered direct offering By Investing.com - Investing.com Canada
Hoth Therapeutics announces closing of $2 million registered direct offering - marketscreener.com
Hoth Therapeutics Announces Closing Of $2 Million Registered Direct Offering - TradingView
Hoth Therapeutics Raises $2M in Registered Direct Offering - National Today
Hoth Therapeutics closes $2 million registered direct offering - Investing.com
Hoth Therapeutics Raises $2 Million in Registered Direct Offering; Issues Five-Year Warrants - TradingView
Hoth Therapeutics (NASDAQ: HOTH) closes $2M registered direct stock deal - Stock Titan
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - PR Newswire
Hoth Therapeutics (NASDAQ: HOTH) raises ~$2.0M; concurrent warrants issued - Stock Titan
Hoth Therapeutics’ HT-001 meets primary endpoint in interim analysis By Investing.com - Investing.com South Africa
Hoth Therapeutics raises $2M in registered direct offering By Investing.com - Investing.com Australia
Hoth Therapeutics raises $2M in registered direct offering - Investing.com
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering - PR Newswire
Hoth Therapeutics’ HT-001 meets primary endpoint in interim analysis - Investing.com
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six - PR Newswire
Hoth Therapeutics receives China patent for mast cell therapy By Investing.com - Investing.com Australia
Energy Moves: Is Hoth Therapeutics Inc stock trending bullish2026 Dividend Review & AI Enhanced Trading Signals - baoquankhu1.vn
Hoth Therapeutics receives China patent for mast cell therapy - Investing.com
Hoth Therapeutics announces issuance of Chinese patent for cancer cell-targeting technology - marketscreener.com
Hoth Therapeutics Announces Issuance Of Chinese Patent For Cancer Cell-Targeting Technology - TradingView
China patent backs Hoth technology designed to kill mast cells - Stock Titan
Moving Averages: Is Hoth Therapeutics Inc a good ESG investment2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Hoth Therapeutics 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, FDA Regulatory Pathways, and Risk Factors Overview - Minichart
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics 10-K: $0 Revenue, $(0.90) EPS, $(12.47)M Net Loss - tradingview.com
Hoth Therapeutics (NASDAQ: HOTH) warns on cash needs and going‑concern risk - Stock Titan
Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Aug Sentiment: Will Hoth Therapeutics Inc stock recover after earningsOptions Play & Weekly Setup with ROI Potential - baoquankhu1.vn
Hoth Therapeutics launches AI platform for drug discovery By Investing.com - Investing.com Canada
Hoth Therapeutics Launches OpenClaw AI for Accelerating Drug Discovery - Contract Pharma
HOTH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hoth Therapeutics Deploys OpenClawtm AI Platform to Accelerate Drug Discovery - Lelezard
Hoth Therapeutics launches AI platform for drug discovery - Investing.com
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery - PR Newswire
EXCLUSIVE: Hoth Therapeutics Targets Faster Drug Discovery With New AI Platform - Benzinga
Hoth Therapeutics (NASDAQ:HOTH) Receives Buy Rating from D. Boral Capital - Defense World
HOTH: Analyst Jason Kolbert Maintains Buy Rating with $5 Target Price | HOTH Stock News - gurufocus.com
Hoth reports positive pharmacokinetic data for topical HT-001 By Investing.com - Investing.com Australia
Hoth reports positive pharmacokinetic data for topical HT-001 - Investing.com
Hoth Therapeutics Reports Positive Ht-001 Pk, Safety, And Clinical Activity Data In Cancer Patients With Egfr Therapy - TradingView
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption - PR Newswire
Hoth Therapeutics stock faces biotech volatility amid pipeline updates and market pressures - AD HOC NEWS
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA - MSN
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
1.51%
1.75%
大文字化:
|
ボリューム (24 時間):